ReviewClinical cardiology2018
The art of cardiovascular risk assessment.
Review in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Methods to assess atherosclerotic cardiovascular risk in chronic respiratory diseases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Phase angle of bioimpedance at 50 kHz is associated with cardiovascular diseases: systematic review and meta-analysis.European journal of clinical nutrition · 2022Pooled it
- Effects of Physical Exercise on Cardiometabolic Health in Individuals with Autism Spectrum Disorder: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- A 10-Year Risk Assessment and Primary Prevention Study of Atherosclerotic Cardiovascular Disease Among Adult Patients in Saudi Arabia: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Estimating the Risk of Cardiovascular Events in U.S. Veterans Using the SMART Risk Score.JACC. Advances · 2025Article
- Exploring the Current Tools in Cardiovascular Risk Assessment in the Middle East and the Need for Region-Specific Models - A Scoping Review.Therapeutics and clinical risk management · 2025Review
- Triglyceride to high density lipoprotein cholesterol ratio and major adverse cardiovascular events in ACS patients undergoing PCI.Scientific reports · 2024Article
- Exploring the association between phase angle of bioimpedance at 50 kHz and cardiovascular risk.BMC cardiovascular disorders · 2024Article
- Ten-year risk assessment for cardiovascular disease & associated factors among adult Indians (aged 40-69 yr): Insights from the National Noncommunicable Disease Monitoring Survey (NNMS).The Indian journal of medical research · 2024Article
- Major Limitations of Cardiovascular Risk Scores.Cardiovascular therapeutics · 2024Review
- Estimation of 10-year cardiovascular risk among adult population in western Nepal using nonlaboratory-based WHO/ISH chart, 2023: A cross-sectional study.Health science reports · 2023Article
- Development of a Cardiovascular Disease Risk Prediction Model: A Preliminary Retrospective Cohort Study of a Patient Sample in Saudi Arabia.Journal of clinical medicine · 2023Article
- Clinical and organizational impact of the use of different cardiac troponin assays for the diagnosis of myocardial infarction without persistent elevation of the ST segment at presentation (NSTEMI) in 12 Italian emergency departments (EDs): the TROCAR study.Internal and emergency medicine · 2023Observational
- Gamma glutamyl transferases in association with cardiovascular risk scores in non-diabetic hypertensive Cameroonians: preliminary data from HYRICCA study.BMC research notes · 2022Article
- The Need for Individualized Risk Assessment in Cardiovascular Disease.Journal of personalized medicine · 2022Review
- Article
- WHO Non-Lab-Based CVD Risk Assessment: A Reliable Measure in a North Indian Population.Global heart · 2022Article
- Article
- Polypills in Cardiovascular Disease Prevention: Mass-Strategy Approach, Precision Medicine, or an Essential Intertwine Between Them?Current atherosclerosis reports · 2021Review
- Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of death in the United States. Healthcare expenditures have been principally allocated toward treatment of CVD at the end of the health/disease continuum, rather than toward health promotion and disease prevention. A focused effort on both primordial and primary prevention can promote cardiovascular health and reduce the burden of CVD. Risk-factor assessment for predicting atherosclerotic CVD events serves as the foundation of preventive cardiology and has been driven by population-based scoring algorithms based on traditional risk factors. Incorporating individual nontraditional risk factors, biomarkers, and selective use of noninvasive measures may help identify more at-risk patients as well as truly low-risk individuals, allowing for better targeting of treatment intensity. Using a combination of validated population-based atherosclerotic CVD risk-assessment tools, nontraditional risk factors, social health determinants, and novel markers of atherosclerotic disease, we should be able to improve our ability to assess CVD risk. Through scientific evidence, clinical judgment, and discussion between the patient and clinician, we can implement an effective evidence-based strategy to assess and reduce CVD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.